CLAIMS

1. (+)-5-(3,4-Difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

2. A pharmaceutical containing as an active ingredient the compound according to claim 1 or a salt thereof.

3. The pharmaceutical according to claim 2, substantially not containing (-)-isomer.

4. The pharmaceutical according to claim 2 or claim 3, wherein 95 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

5. The pharmaceutical according to claim 4, wherein 98 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

6. The pharmaceutical according to claim 5, wherein 99.5 weight % or more of the total amount of the 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof in the pharmaceutical is (+)-isomer.

7. The pharmaceutical according to any one of claims 2 to 6, wherein the pharmaceutical is an external preparation.

8. The pharmaceutical according to claim 7, wherein the external preparation is selected from the group consisting of a lotion, cream, liquid and ointment.

9. The pharmaceutical according to claim 7 or 8, containing pharmaceutically acceptable glycols.

10. The pharmaceutical according to claim 9, wherein the pharmaceutically acceptable glycols is propylene glycol or butylene glycol.

11. The pharmaceutical according to any one of claims 7 to 10, containing water in the formulation.

12. The pharmaceutical according to any one of claims 7 to 11, containing as an active ingredient 1 w/w% or more (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

13. The pharmaceutical according to claim 12, containing as an active ingredient 3 w/w% or more (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.

14. A method of producing (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, comprising optically resolving a racemate (±)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by chromatography using a column for optical separation.

15. A mixture of (+)- and (-)-isomers of 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, wherein the (+)-isomer exists at 90 %ee or more to the (-)-isomer.

16. The mixture according to claim 15, wherein the (+)-isomer exists at 96 %ee or more to the (-)-isomer.

17. The mixture according to claim 15 or 16, wherein the (+)-isomer exists at 99 %ee or more to the (-)-isomer.

18. Use of a compound according to claim 1 in the manufacture of a medicament for treating and preventing a skin disease.

19. The use according to claim 18, wherein the skin disease is one or more skin disease(s) selected from the group consisting of a localized scleroderma, atopic dermatitis, contact dermatitis, psoriasis, and acne.